Reviewing Nuvation Bio (NYSE:NUVB) and BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Earnings and Valuation

This table compares BioLineRx and Nuvation Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18 million	9.68	-$1.17 million	($1.69)	-1.39
Nuvation Bio	$169.90 million	11.65	-$204.63 million	($0.44)	-12.81

BioLineRx has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioLineRx and Nuvation Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Risk and Volatility

BioLineRx has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioLineRx and Nuvation Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	0	0	1.00
Nuvation Bio	1	2	9	0	2.67

Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 134.64%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than BioLineRx.

Insider and Institutional Ownership

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Nuvation Bio beats BioLineRx on 9 of the 14 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.